DK2448637T4 - Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi - Google Patents

Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi Download PDF

Info

Publication number
DK2448637T4
DK2448637T4 DK10734541.5T DK10734541T DK2448637T4 DK 2448637 T4 DK2448637 T4 DK 2448637T4 DK 10734541 T DK10734541 T DK 10734541T DK 2448637 T4 DK2448637 T4 DK 2448637T4
Authority
DK
Denmark
Prior art keywords
phytocannabinoid
phytocannabinoids
epilepsy
treatment
combination
Prior art date
Application number
DK10734541.5T
Other languages
English (en)
Other versions
DK2448637T3 (da
Inventor
Ben Whalley
Gary Stephens
Claire Williams
Geoffrey Guy
Stephen Wright
Tetsuro Kikuchi
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2448637(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Application granted granted Critical
Publication of DK2448637T3 publication Critical patent/DK2448637T3/da
Publication of DK2448637T4 publication Critical patent/DK2448637T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
DK10734541.5T 2009-07-03 2010-06-29 Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi DK2448637T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
DK2448637T3 DK2448637T3 (da) 2014-05-26
DK2448637T4 true DK2448637T4 (da) 2022-09-12

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10734541.5T DK2448637T4 (da) 2009-07-03 2010-06-29 Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi

Country Status (29)

Country Link
US (4) US9066920B2 (da)
EP (3) EP2727626A1 (da)
JP (2) JP5904938B2 (da)
KR (1) KR101727000B1 (da)
CN (2) CN106236744A (da)
AR (1) AR077448A1 (da)
AU (1) AU2010267775C1 (da)
BR (1) BR112012000076A2 (da)
CA (2) CA3040410C (da)
CY (1) CY1115338T1 (da)
DK (1) DK2448637T4 (da)
ES (1) ES2460623T5 (da)
GB (3) GB2471523A (da)
HK (1) HK1164766A1 (da)
HR (1) HRP20140398T4 (da)
IL (1) IL217280B (da)
IN (1) IN2012DN00804A (da)
MX (1) MX2012000257A (da)
MY (1) MY156759A (da)
NZ (2) NZ620838A (da)
PL (1) PL2448637T5 (da)
PT (1) PT2448637E (da)
RU (1) RU2563143C2 (da)
SG (1) SG176914A1 (da)
SI (1) SI2448637T2 (da)
TW (1) TWI461191B (da)
UA (1) UA108852C2 (da)
WO (1) WO2011001169A1 (da)
ZA (1) ZA201200373B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
CA2981285A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
JP2018514540A (ja) * 2015-04-28 2018-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 点頭てんかん治療へのカンナビジオールの使用
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
AU2016359160A1 (en) 2015-11-24 2018-06-14 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
MX2022003193A (es) * 2019-09-17 2022-04-11 Zynerba Pharmaceuticals Inc Tratamiento de encefalopatia asociada al gen syngap1.
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
MX2023001129A (es) 2020-07-28 2023-03-27 Impello Biosciences Inc Metodos y composiciones para alterar metabolitos secundarios en plantas.
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
WO2023009817A2 (en) 2021-07-29 2023-02-02 Emory University Phosphate prodrugs of cannabinoids
WO2023200906A1 (en) * 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
DK2311475T3 (da) 2002-08-14 2016-09-19 Gw Pharma Ltd Ekstrahering af farmaceutisk aktive cannabinoider fra plantematerialer
CA2454644C (en) * 2002-08-14 2014-09-16 Gw Pharma Limited Cannabinoid liquid formulations for mucosal administration
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US9877928B2 (en) 2006-05-30 2018-01-30 Air Systems, Inc. Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
PT2280687T (pt) 2008-03-26 2019-06-04 Stichting Sanammad Composições de goma de mascar compreendendo canabinóides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
WO2013032351A1 (en) 2011-08-26 2013-03-07 BIAL - PORTELA & Cª, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
IL302782A (en) 2014-05-29 2023-07-01 Radius Pharmaceuticals Inc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy

Also Published As

Publication number Publication date
AU2010267775B2 (en) 2016-10-06
US9066920B2 (en) 2015-06-30
EP2448637B1 (en) 2014-03-12
JP2012532093A (ja) 2012-12-13
CA2766082A1 (en) 2011-01-06
CY1115338T1 (el) 2017-01-04
PT2448637E (pt) 2014-05-27
US20120165402A1 (en) 2012-06-28
GB0911580D0 (en) 2009-08-12
ES2460623T3 (es) 2014-05-14
SG176914A1 (en) 2012-01-30
EP2448637B2 (en) 2022-06-08
GB2471523A (en) 2011-01-05
IL217280B (en) 2018-05-31
JP5904938B2 (ja) 2016-04-20
KR20120088648A (ko) 2012-08-08
CN106236744A (zh) 2016-12-21
GB2485291A (en) 2012-05-09
MY156759A (en) 2016-03-31
PL2448637T3 (pl) 2014-08-29
EP2448637A1 (en) 2012-05-09
WO2011001169A1 (en) 2011-01-06
GB201010897D0 (en) 2010-08-11
HK1164766A1 (en) 2012-09-28
UA108852C2 (ru) 2015-06-25
EP2727626A1 (en) 2014-05-07
PL2448637T5 (pl) 2022-10-03
TW201105318A (en) 2011-02-16
AU2010267775A1 (en) 2012-02-23
RU2563143C2 (ru) 2015-09-20
ZA201200373B (en) 2012-09-26
US20170273913A1 (en) 2017-09-28
MX2012000257A (es) 2012-01-27
AU2010267775C1 (en) 2020-02-27
GB2485291B (en) 2013-03-27
JP2016166205A (ja) 2016-09-15
DK2448637T3 (da) 2014-05-26
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
US9522123B2 (en) 2016-12-20
HRP20140398T4 (hr) 2022-10-14
AR077448A1 (es) 2011-08-31
RU2012103603A (ru) 2013-08-10
BR112012000076A2 (pt) 2020-06-02
US20190247324A1 (en) 2019-08-15
US20150335590A1 (en) 2015-11-26
KR101727000B1 (ko) 2017-05-02
SI2448637T1 (sl) 2014-07-31
GB2471565B (en) 2012-07-04
ES2460623T5 (es) 2022-10-14
SI2448637T2 (sl) 2022-10-28
IL217280A0 (en) 2012-02-29
CA3040410C (en) 2023-03-28
GB2471565A (en) 2011-01-05
CA3040410A1 (en) 2011-01-06
HRP20140398T1 (hr) 2014-06-20
CA2766082C (en) 2019-06-11
IN2012DN00804A (da) 2015-06-26
NZ597704A (en) 2014-05-30
CN102596322A (zh) 2012-07-18
TWI461191B (zh) 2014-11-21
NZ620838A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
DK2448637T4 (da) Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
BRPI1013389A2 (pt) fivela
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2229927T3 (da) Fleksibel beholder med indskydelig del
FI20095433A0 (fi) Mikroneula
UA21022S (uk) Пряжка
DK2435583T3 (da) miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
DK2501381T3 (da) Behandling af atrieflimmer
FI20095671A (fi) Lukitusjärjestely
BR112012006693A2 (pt) combinação
BR112012006968A2 (pt) combinação
IT1391542B1 (it) Cassaforte
HK1173995A1 (en) Use of ferroquine in the treatment of malaria
EE00869U1 (et) Korduvkasutusega martappliide
BRPI1004552A2 (pt) catéter
BRPI1013017A2 (pt) "17beta-alquil-17alfa-óxi-estratrienos"
TH123099B (th) ไดไฮโดรไพราโซโลนที่ถูกแทนที่และการใช้ของมัน
ES1070687Y (es) Gafas de natacion
FI20090498A0 (fi) Hengityssuojain
FI8477U1 (fi) Keräin
ITBO20090176A1 (it) Esca artificiale
FI8274U1 (fi) Kestovaippa
IT1393631B1 (it) Raspa podologica con abrasivo monouso
ES1070358Y (es) Tenaza orientable
ES1070644Y (es) Babero infantil